Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin (PONTiAK) Trial: A Phase 2B Vanguard Design, Randomized, Double-Blind, Placebo-Controlled Study

Next Previous
Trial Profile

The Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin (PONTiAK) Trial: A Phase 2B Vanguard Design, Randomized, Double-Blind, Placebo-Controlled Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilastatin (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Acronyms PONTiAK
  • Sponsors Arch Biopartners

Most Recent Events

  • 22 Jul 2025 Accoring to Arch Biopartners media release, company announced that this trial has commenced patient recruitment at its primary clinical sites in Alberta, Canada
  • 22 Jul 2025 Planned number of patients changed from 900 to 698, accoring to Arch Biopartners media release.
  • 22 Jul 2025 Status changed from planning to recruiting, Accoring to Arch Biopartners media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top